Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers at the University of Oxford are investigating the long-term health outcomes for patients who have been treated for severe COVID-19 disease in intensive care.

Image of a calendar © Photo by Eric Rothermel on Unsplash

To date, over 12,000 patients have been treated on an Intensive Care Unit (ICU) in England, Wales and Northern Ireland for very severe COVID-19 disease. Around 60% of them have survived to leave hospital, after an average of 11 days of care. Scientists are not only unclear on the long-term effects of the disease itself; they also know very little about the impact of a stay in ICU on these patients.

Before the COVID-19 outbreak, the Oxford Critical Care Research Group (CCRG) had developed efficient approaches to systematically follow up ICU patients over the long term. Their approach involves linking data from the Case Mix Programme, to which ICUs report, to multiple other routine healthcare data sources, through NHS Digital.

This new study funded by The University of Oxford's COVID-19 Research Response Fund will look at key six-month health outcomes in patients who survived severe COVID-19 in England. It will provide timely data on additional risks faced by survivors that might be mitigated by specialist or community follow-up.

Stephen Gerry, Senior Medical Statistician at NDORMS commented: "Understandably, due to the incredibly large numbers of people affected, more attention is being given to the long term prospects of patients who have had severe COVID-19. This is an exciting project, because uniquely we will be able to follow all patients who have been discharged from ICUs in England, Wales, or NI, having recovered from COVID-19. It is a great opportunity to gain a clear understanding of what will happen to these patients, and we hope that our research will help inform clinical practice."

It is hoped that this initial study will lead to further research on longer-term follow-up, with a wider range of patient outcomes.

Similar stories

Small mechanical forces in immune cells measured at unprecedented sensitivity

Kennedy Main Research

Oxford researchers have used advanced microscopy techniques to measure previously unseen forces generated by cells during an immune response; a breakthrough for mechanobiology and future advances in health and disease.

NDORMS researchers awarded for Dupuytren research

Awards Hand Kennedy Main

Three NDORMS researchers have received awards from the International Dupuytren Society, a patient organisation that brings together Dupuytren Disease patient societies from across the world.

Hope for rheumatoid arthritis patients who are non-responsive to anti-TNF

Arthritis Kennedy Main

New research published in The Lancet shows that tocilizumab is a more effective treatment than rituximab for rheumatoid arthritis patients with a poor response to anti-tumour necrosis factor (TNF).

A new study maps the expression of innate immune receptors during the course of arthritis

Arthritis Kennedy Main

The research, which was a collaboration with researchers from Oxford University and Queen Mary University of London and published in Journal of Autoimmunity, looked at changes in receptors known as toll-like receptors (TLRs) in arthritis at different stages of disease.

International Women's Day

Department Main

It’s International Women's Day! This year’s theme is #Choosetochallenge. We’re celebrating some of the amazing women at NDORMS, and asking them what changes they’d like to see in medical sciences over the next 100 years.

Patients and carers invited to join new group helping to shape research and treatment of bones, muscles and joints

Main PPI

Oxford’s newest patient partner group, OPEN ARMS launches today to explore the causes, treatment and care for patients with musculoskeletal conditions. Its first three patient partners explain why they are involved and invite other members of the public to join the team.